Combination Therapy with Aripiprazole and Cariprazine

Mechanism of Action and Efficacy

Antipsychotic polypharmacy, including the combination of aripiprazole and cariprazine, may be beneficial in cases where monotherapy with non-clozapine antipsychotics and clozapine have failed or when clozapine is contraindicated, as suggested by the available evidence 1, 2
Combining partial dopamine agonists like aripiprazole and cariprazine may be particularly effective in reducing residual symptoms while minimizing side effects, according to research findings 3
The combination of aripiprazole and cariprazine may allow for lower doses of each medication, potentially reducing the risk of side effects while maintaining efficacy, as indicated by studies 5
Negative symptoms, which are typically difficult to treat with monotherapy, may show greater improvement with this combination due to cariprazine's unique D3 receptor affinity, as reported in research 4

A meta-analysis found that antipsychotic augmentation was superior to monotherapy regarding total symptom reduction, particularly when using partial dopamine agonists, providing evidence for the efficacy of combination therapy 5
Real-world evidence from a large cohort (n=62,250) showed that patients had a 7-13% lower risk of psychiatric hospitalization when treated with antipsychotic polypharmacy versus monotherapy, highlighting the potential benefits of combination therapy 7
The American Psychiatric Association recommends antipsychotic monotherapy as first-line treatment, but acknowledges that certain antipsychotic combinations may be beneficial for specific patient populations, as supported by evidence 1, 6

Careful monitoring for side effects is essential when using the combination of aripiprazole and cariprazine, as it may carry an increased risk of extrapyramidal symptoms compared to monotherapy, emphasizing the need for close patient monitoring 8
The combination should be initiated with lower doses of each medication than would be used in monotherapy, and patients should be monitored closely for akathisia and extrapyramidal symptoms, especially in the first few weeks, as recommended by clinical guidelines 5, 8